Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...
Hosted on MSN18h
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?Arcutis Biotherapeutics, Inc. (ARQT) shares rallied 15.9% in the last trading session to close at $13.21. This move can be attributable to notable volume with a higher number of shares being traded ...
PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...
A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. Other equities ...
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback